Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cidoxepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | DRD2 | P14416 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxepin SCHEMBL1281891 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL3408702 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Cidoxepin SCHEMBL29368454 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL29359800 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| E-Doxepin SCHEMBL60287 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL41532 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL29018844 | 0.99 | ALDH1A1 (0.97) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Cidoxepin SCHEMBL684837 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL31349647 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL28054 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0338532-A2 | N-alkylamino derivates of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | HRH1 530/4885SLC6A2 286/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.